UNSPSC 51311805: Mapinastine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62LN840SFZ. European Medicines Agency schedules Mapinastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08646MIG. Mapinastine generally arises in the molecular formula C23H34N6O.

UNSPSC 51311805 Mapinastine, a Commodity code, covers pharmaceutical and pharmaceutical-adjunct products that state and local governments procure for community health, public health emergency response, and population health initiatives. The recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for opioid response, generic pharmaceuticals and over-the-counter products through multistate cooperative purchasing, and therapeutic pharmacy services through direct-to-manufacturer contracting models. Issuing bodies include county health departments, state health and human services commissions, and regional multistate cooperative purchasing alliances. Work ranges from one-time or recurring supply contracts with fixed annual volumes to exploratory requests for information that inform future formal solicitations and procurement strategy.

Activity appears across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment models for a future Therapeutic Pharmacy Initiative program. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with a proposals deadline of March 26, 2026, and contract effectiveness date of July 1, 2026.